$UTHR develops therapies for pulmonary hypertension and other serious conditions, alongside a growing technology pipeline. Its chart remains below a descending

$UTHR develops therapies for pulmonary hypertension and other serious conditions, alongside a growing technology pipeline. Its chart remains below a descending support boundary. The line slopes from roughly $536.39 toward $508.15, and rebounds failed near $541.03 and $535.77 before price made a fre…